IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2.
[1][2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported.
[1] The drug is an antisense oligonucleotide against the glucocorticoid receptor.
[1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.
[1] This hormonal preparation article is a stub.